We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


DiscoveRx Corporation Signs Agreement with Cosmo Bio

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DiscoveRx Corporation Signs Agreement with Cosmo Bio"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

DiscoveRx Corporation announces the selection of Cosmo Bio Co., Ltd. as a key distributor for the Japanese territory.

“Cosmo Bio's leadership in providing third party drug discovery services to the Japanese pharmaceutical and biotech industries and in the distribution of products for life science research is well recognized throughout Japan. We believe that the addition of DiscoveRx Corporation’s Selectivity Screen™ GPCR profiling services will significantly benefit Cosmo Bio’s customers,” said Theresa Schaub, Director, Drug Discovery Screening Services at DiscoveRx.

Dr. Haruhisa Sakurai, Director of Cosmo Bio’s Drug Discovery Services team, remarked, “Many drugs relate to their effects via a family of proteins called G-protein-coupled receptors (GPCR). Many industries have focused the development of drugs as one of important targets. To accelerate discovery of more selective screening for disease, we are very excited by the opportunity to offer GPCR Profiling Service by DiscoveRx to Japanese customers.”

Additionally, DiscoveRx Corporation continues to add targets to its discovery service offering. The recent introduction of Nuclear Hormone Receptors, Kinases and Orphan GPCRs complement DiscoveRx Corporation’s PathHunter™ Cell Based Assays, HitHunter™ Biochemical Assays and screening reagents. Global adoption of the PathHunter™ EFC technology has contributed to discovery of compounds worldwide.